Patient Materials
Here are some helpful materials for your own use. Just click on the link and print
out any or all of these resources. You can also read an excerpt from A Guide to
Living With von Willebrand Disease.
Medications to Avoid
Here you’ll find a listing of medications to avoid if you have VWD.
Activities to Enjoy
This page has information on recommended physical activities if you have VWD.
My Journal
If you are a woman with VWD, use this journal to keep track of your periods and
related information. It can also be a helpful tool for your next visit with your
doctor.

A Guide to Living With von Willebrand Disease: Complete a quick registration page
and we will send you this guide—the first book-length resource about VWD. A Guide
to Living With von Willebrand Disease was written by Renée Paper, RN, a healthcare
professional with VWD, and Laureen A. Kelley, author and mother of a child with
hemophilia.
Renée was a tireless advocate for people with bleeding disorders, especially VWD.
She passed away in November 2007, but her contributions to the bleeding disorders
community will live on. Laureen is the author of numerous books on bleeding disorders
and the president of LA Kelley Communications, Inc., a provider of educational resources
and leadership training for the bleeding disorders community.
A Guide to Living With von Willebrand Disease provides valuable information on living
with the disease. Read an excerpt
right now and view the front and back covers, foreword, and preface by clicking
the images below.
Important Safety Information
Humate-P is indicated for treatment and prevention of bleeding in adult patients
with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and
pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous
and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during
and after surgery. This applies to patients with severe VWD, and patients with mild
and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.
Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.
Humate-P is contraindicated in individuals with a history of anaphylactic or severe
systemic response to antihemophilic factor or von Willebrand factor preparations.
Monitor for intravascular hemolysis and decreasing hematocrit values in patients
with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor
VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.
Thromboembolic events have been reported in VWD patients receiving coagulation factor
replacement. Caution should be exercised and antithrombotic measures considered,
particularly in patients with known risk factors for thrombosis.
Humate-P is derived from human plasma. The risk of transmission of infectious agents,
including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent,
cannot be completely eliminated.
In patients receiving Humate-P in clinical studies for treatment of VWD, the most
commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic
reactions, including urticaria (hives), chest tightness, rash, pruritus (itching),
and edema (swelling). For patients undergoing surgery, the most common adverse reactions
are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).
Please see full prescribing
information.
You are encouraged to report negative side effects of prescription drugs to the
FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
© CSL Behring 2010. The product information presented on this site is intended for US residents only.